

Goldman may convert part-debt into equity in PharmEasy
Goldman Sachs is likely to convert a part of the debt it advanced to PharmEasy into equity, following the upcoming rights issue of about $424 million (Rs 3,500 crore) by the online pharmacy that is due to open on September 4, sources aware of the matter said.
Goldman, which had issued a $300-million loan to PharmEasy, is in talks to convert around $38-40 million debt into equity. The rights issue is likely to value the e-pharmacy at $500-600 million. This is significantly lower than its peak valuation of $5.6 billion in 2021.
Elevate Your Tech Process with High-Value Skill Courses
Offering CollegeCourseWebsiteIndian School of BusinessISB Product ManagementVisitIndian School of BusinessISB Digital Marketing and AnalyticsVisitIndian School of BusinessISB Digital TransformationVisitIndian School of BusinessISB Applied Business AnalyticsVisitFollowing binding commitments from existing investors in the rights issue, PharmEasy is restructuring the debt agreement with Goldman, negotiating for a lower rate of interest on the total loan. “The rights issue is slated to start September 4 and based on commitment from existing investors, the cash-position of the firm is looking better than six months ago. This has led to the (discussions about) restructuring debt terms and a conversion to equity,” said one person aware of the talks.
Likely to Repay $100-150 million of Debt
PharmEasy — which also owns diagnostics firm Thyrocare — is also likely to pay back about $100-150 million of debt to Goldman following the rights issue, according to sources in the know. Currently, PharmEasy has an obligation of Rs 30 crore (around $3.6 million) in quarterly interest payout.
“It (payback amount) could even hit $200 million based on how much money